Empowering Cancer Patients: Understanding and Preventing Thrombosis
Cancer patients face numerous challenges on their journey, and one often overlooked concern is the increased risk of...
AUTHORS
Editor in chief - Anna Falanga
Professor of hematology, University of Milano-Bicocca, Department of Medicine and Surgery, Milan and Hospital Papa Giovanni XXIII, Bergamo, Italy.
Anna Falanga, MD, is Chief of the Department of Immunohematology and Transfusion Medicine and the Thrombosis and Hemostasis Center, at the Hospital Papa Giovanni XXIII, in Bergamo, Italy. Author of more than 280 publications and guest editor of 15 volumes, she is appointed as professor at the School of Hematology, University Bicocca Milan, and at the faculty of Health Engineering, University of Bergamo, Italy. She sits on board of the Council of the International Society of Thrombosis and Haemostasis (ISTH). In 2009 she received the BACH Investigator Award of the ISTH, and in 2015 the "Harold R. Roberts Medal 2015" of the SSC of ISTH.
Other activities of Anna Falanga include the organization of numerous scientific conferences, including the co-chairmanship of International Conferences on "Thrombosis and Hemostasis Issues in Cancer" (ICTHIC).
Anna Falanga, MD, is Chief of the Department of Immunohematology and Transfusion Medicine and the Thrombosis and Hemostasis Center, at the Hospital Papa Giovanni XXIII, in Bergamo, Italy. Author of more than 280 publications and guest editor of 15 volumes, she is appointed as professor at the School of Hematology, University Bicocca Milan, and at the faculty of Health Engineering, University of Bergamo, Italy. She sits on board of the Council of the International Society of Thrombosis and Haemostasis (ISTH). In 2009 she received the BACH Investigator Award of the ISTH, and in 2015 the "Harold R. Roberts Medal 2015" of the SSC of ISTH.
Other activities of Anna Falanga include the organization of numerous scientific conferences, including the co-chairmanship of International Conferences on "Thrombosis and Hemostasis Issues in Cancer" (ICTHIC).
Summary ESMO Clinical Practice Guideline for the management of venous thromboembolism in cancer patients
Venous thromboembolism (VTE) is the second cause of death in people with cancer, after cancer itself. Cancer and VTE...
The USCAT study: a retrospective non-interventional study to examine long-term treatment of CAT
Patients with cancer are at high risk of venous thromboembolism (VTE) recurrence and major bleeding (1). Most...
PATIENTS’ EXPERIENCE OF LIVING WITH CANCER-ASSOCIATED THROMBOSIS: THE PELICAN PROJECT
The clinical issues and the main consequences of venous thromboembolism (VTE) in patients with cancer are nowadays well...
COVID-19 Hemostasis and Malignancy: the Bergamo Experience
The COVID-19 pandemic took one of its biggest tolls on Italy, and especially in the northern area, in Lombardy. In this...
Fundamental research in oncology and thrombosis – the Frontline experience
What is the physician perception and common practice in treatment of venous thromboembolism (VTE) in cancer patients?...
COVID-19 and Management of Thrombotic Disease
The coronavirus disease 2019 (COVID-19) pandemic has posed a series of new questions in management of patients....
Impact of COVID-19 on healthcare workers and health systems
After the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, the adoption of specific personal...
Prophylaxis for venous thromboembolism in COVID-19 Patients
The development of venous thromboembolism (VTE) is one of the major consequences observed in patients with Coronavirus...
Coagulopathy and thrombosis in COVID-19 patients: parameters to be checked to assess disease severity
As the clinical evidence keeps on accumulating, we can clearly state that coronavirus disease 2019 (COVID-19) very...